At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Psilocybin 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
In Brief
A Phase 2 clinical trial evaluating Psilocybin for Body Dysmorphic Disorders. Completed, enrolled 12 participants across 1 site.
Detailed Summary
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBody Dysmorphic Disorders
CountriesUnited States
CollaboratorsCOMPASS Pathways, University of California, Los Angeles
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedDec 7, 2020
Enrollment StartFeb 26, 2021
Primary CompletionNov 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.6 years ago
Interventions
Psilocybindrug
A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute